Trial Profile
Therapy Evaluation With Kaletra: 5 Year Long-term Effect in Patients With Non-B-subtypes Infections.
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Mar 2013
Price :
$35
*
At a glance
- Drugs Lopinavir/ritonavir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- Sponsors Abbott Laboratories
- 18 Nov 2010 Additional lead trial investigator (Stefan Simianer) identified as reported by ClinicalTrials.gov.
- 10 Mar 2010 New trial record